Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PLA2G10 | O15496 | 9/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9986981 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TSHRPLA2G10NOTUMF10 | |
| SCHEMBL9986521 | 0.80 | NOTUM (0.42) | PLA2G10NOTUM | |
| SCHEMBL9987772 | 0.79 | PDE4B (0.49) | — | |
| SCHEMBL9987033 | 0.74 | NOTUM (0.42) | ALDH1A1TSHRPLA2G10NOTUMF10 | |
| SCHEMBL9986971 | 0.74 | NOTUM (0.45) | ALDH1A1TSHRPLA2G10NOTUMF10 | |
| SCHEMBL9987074 | 0.72 | NOTUM (0.46) | TSHRNOTUM | |
| SCHEMBL9149430 | 0.72 | ALDH1A1 (0.79) | ALDH1A1TSHRPLA2G10NOTUMMCL1 | |
| SCHEMBL28393384 | 0.72 | ALDH1A1 (0.69) | ALDH1A1TSHRPLA2G10F10MCL1 | |
| SCHEMBL5208338 | 0.72 | ALDH1A1 (1.00) | ALDH1A1TSHRPLA2G10MCL1DAO | |
| SCHEMBL30194196 | 0.72 | ALDH1A1 (1.00) | ALDH1A1TSHRPLA2G10MCL1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062055-B2 | Fused pyrrole derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| WO-2011163195-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163195-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312979-A1 | FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R4, PIK3CA | ALDH1A1 3993/4885TSHR 1960/4885PLA2G10 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.